---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-280172"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:29:40.155691+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Acrivon Therapeutics Q3 2025 net loss $18.2M, cash $134.4M to fund into Q2 2027

## Summary
- Net loss of $18.2M for Q3 2025, improved from $22.4M in Q3 2024.
- Cash, cash equivalents and investments of $134.4M as of Sep 30, 2025; funds operations into Q2 2027.
- R&D expenses fell to $13.6M from $18.9M due to fewer milestones and trial prioritization.
- Advancing ACR-368 Phase 2b trial for endometrial cancer; initial ACR-2316 Phase 1 data expected H2 2025.
- Presented AP3 platform data at AACR-NCI-EORTC; new cell cycle program targets candidate nomination in 2025.

## SEC filing metadata
- accession: 0001193125-25-280172
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312525280172/0001193125-25-280172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312525280172/acrv-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-280172
- JSON: https://secwatch.observer/filing/0001193125-25-280172.json
- Plain text: https://secwatch.observer/filing/0001193125-25-280172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.